Escolar Documentos
Profissional Documentos
Cultura Documentos
UNICHEM
Investor Presentation
Q3 & 9M FY 2016
UNICHEM
No part of this presentation may be reproduced, quoted or circulated without the prior
approval from Unichem Laboratories Limited
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
Profile
One of the Indias leading integrated Pharmaceutical Companies with a
strong presence in domestic formulations market
Ranked 26th in the Domestic Formulations market as per AWACS MAT December 2015
Amongst the top # 18 companies in representative (covered) market
Domestic Operations contribute ~59% of Consolidated Revenues
International Operations contribute ~41% of Consolidated Revenues
US revenues showing a robust growth
Dedicated focus on International operations gaining momentum
UNICHEM
Dec, 2015)
Acquisition of
100% stake
in Niche
Generics
2005-06
New PTD at
Goa
Baddi II
commissioned
Acquisition of
API plant at
Pithampur
USFDA
certification
of Ghaziabad
Plant
EDQM
certification
of Roha
Plant
2007-08
USFDA
re-certification of
Goa Plant &
Roha Plant
Commencement
of Sikkim &
Baddi
USFDA
Formulation
certification of Plant
API plant at
Pithampur
Commencement
of US sales
Construction
of R & D
Centre at
Goa started
UNICHEM
2009
Sikkim
Goa
Factory
BioScience
construction
R&D
started
commissioned
Launch of
Unikare Derma
Division
Expansion of
Packaging
facility at
Goa Plant
Re-location
of R&D from
Mumbai to
Goa (CoE).
Filings
commissione
d from new
R&D Centre
Sale of Indore
SEZ plant to
Mylan
Laboratories Ltd.
USFDA recertification of
API plant
Pithampur
Establishment
of packing
unit at Ireland
2010-11
Modernization of
Betalactum
Plant - Baddi
SEZ Pithampur
construction
started
Reorganization
of Acute
Business
2012
USFDAs surprise
inspection at 3 plants
EIR received, thereby
enabling business
continuity in US
2013-14
Realignment of Chronic
Purchase of
business.
additional
Commenced further
land at Goa
sub divisionalization
with increased focus on
Chronic, launching new
division on Cardio &
Neuro.
Commencement of
expansion at API facility
in Pithampur
Acquiring API facility in
Kolhapur, Maharashtra
2015-16
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
1,400
18.0%
16.1%
15.7%
16.0%
1,200
13.5%
1,133
1,081
1,000
1,202
1,003
UNICHEM
11.6%
876
800
600
8.4%
14.0%
12.0%
10.0%
8.0%
6.0%
400
4.0%
200
2.0%
0.0%
FY 2012
FY 2013
FY 2014
Revenue
FY 2015
9M FY 2016
EBITDA Margin
25
51
50
50
48
44
40
19.1
18.6
18.2
UNICHEM
32
30
20
43
15
33
34
34
15
11.3
11.1
10
13.8
13
12
20
15
8
10
5.8
0
Q1 FY14 Q2 FY14 Q3 FY14 Q4 FY14 Q1 FY15 Q2 FY15 Q3 FY15 Q4 FY15 Q1 FY16 Q2 FY16 Q3 FY16
EBITDA INR Crs
EBITDA Margins %
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
128
11%
230
19%
90
7%
67
6%
71,
6%
UNICHEM
651
55%
455,
38%
675,
56%
23
2%
Formulation - Domestic
API - Domestic
Formulation - Exports
API - Exports
International Business -US/Brazil
International Business - Niche/EU
Unichem Laboratories Ltd
India Business
Regulated Markets
Emerging Markets
10
123,
12%
179,
8%
52,
5%
UNICHEM
360,
36%
55,
6%
572,
57%
591,
59%
49,
5% 18,
2%
Formulation - Domestic
API - Domestic
Formulation - Exports
India Business
Regulated Markets
Emerging Markets
API - Exports
International Business -US/Brazil
Unichem Laboratories Ltd
11
Portfolio
Therapy Dominance & Price Control
SCENE
Therapy
Therapy
UNICHEM
Portfolio
Price Control
Price Control
12
168.4
FY
2010
FY
2011
FY
2012
FY
2013
FY
2014
FY
2015
9M FY
2016
Cumulative
188.7
179.6
152.1
201.3
235.9*
166.5
152.2
1,445
Spending:
R&D
Expenditure
23.5
Capital
Expenditure
45.5
Investment in
Subs
UNICHEM
29.7
40.5
39.7
36.4
52.2
65.4
40.7
328
44.3
84.2
106.5
76.1
86.3
78.6
103.3
625
19.0
10.0
11.0
14.2
20.6
7.6
7.2
5.4
95
Dividend
Payments
21.1
33.8
42.1
29.4
31.5
90.0
42.4
21.9
312
Increase in
Working
Capital
42.7
19.1
54.9
(15.4)
1.3
82.3
8.2
(3.1)
190
16.6
51.8
(53.1)
(22.3)
35.4
71.3
(35.4)
(15.9)
48
Others (Incl
Cash Equivalents
and Deposits)
Note: * Excluding one time gain from sale of Indore SEZ plant to Mylan Laboratories Limited
Unichem Laboratories Ltd
13
Sr. No
% Growth
96,289
14.4
46,611
12.7
UNICHEM
5,070
13.7
Alkem
2,549
13.2
Mankind
2,159
14.8
Cipla
2,035
13.7
Zydus
2,006
6.6
Lupin
1,904
14.5
Macleods
1,787
13.5
Abbott Healthcare
1,735
11.1
Aristo
1,600
18.4
10
Intas
1,449
18.9
18
Unichem Labs
889
11.1
14
% of Total
Value
No. of SubSegments
% of Total
No. of
Segments
49,678
51.6%
2,601
87.7%
46,611
48.4%
365
12.3%
Total Market
96,289
100.0%
2,966
100.0%
UNICHEM
Unichem is represented in 365 sub-segments (about ~12 % of total subsegments), but covers nearly half of the IPM in value terms
However, opportunity does exist for more Unichem introductions in high growth
non-represented segments
Acute Therapy
CNS & Nephrology
Source: AWACS MAT Dec, 2015
15
Chronic
Covered
Specialist
(6)
CVS-Life
CVS-Star
Anti-Hypertensive, Statins
& Anti-Anginal
Cardiologists, Diabetologists,
CPs & FPs
CD
Anti-Hypertensive, Statins,
Diabetes mngmt
UNICHEM
Cardio-Diabeto
(4)
Integra
Neuropsychiatry
(2)
NeuForeva
UniForeva
Anti-Hypertensive, Statins
, Diabetes mngmt &
Related diseases
Anti-Psychotic, Anxiolytics,
Anti-Migraine, & AntiDepressant
Cardiologists, Diabetologists,
CPs & FPs
Cardiologists, Diabetologists,
Nephrologists & CPs
16
Acute
Covered
Specialist
(5)
AntiInfective/Allergy &
Gastro (2)
Pain
Management/
Gastro (1)
UVA
Anti-Infective &
Gastrointestinal, AntiPyritic & related products
Vector
Anti-Infective, Multi
Vitamins, NSAIDs, &
Respiratory
UNICHEM
Vitus
Orthopedics, Surgeons,
& CPs
Derma-Gynec
(1)
Unikare
Anti-Allergic, Antioxidants,
Revitalizers, Haircare,
Infertility, Contraceptives,
Hormones etc.
Intensive Care
Management
(1)
Lifecare
Dermatologists
&
Gynecologists
17
UNICHEM
Chronic Coverage
Cardiologists, Diabetologists, Neurologists, Psychiatrists, Nephrologists,
Gynaecologists (Infertility treatment), CPs, GPs etc.
Acute Coverage
GPs, CPs, NGPs, ENTs, Dentists, Surgeons, Paediatrics, Gynaecologists
(General), Dermatologists, etc.
18
UNICHEM
AntiDiabetic, 3%
MusculoSkeletal, 4%
Others, 7%
GI, 13%
CVS, 42%
CNS, 13%
Anti
Infective,
18%
19
Losar H, Ampoxin, Unienzyme, Losar, Vizylac,Trika, Serta, Unistar, Telsar, and Telsar-H
UNICHEM
#
#
#
#
#
20
Total Revenue
Losar Group
Ampoxin Group
Unienzyme
Telsar Group
Olsar Group
Vizylac
Trika Group
Pregaba Group
Serta
Metride Group
MAT Dec,
2015
%
Growth
% Market
Share
%
Contribution
to Revenue
889
11.1
0.9
100.0
175
13.4
34.8
20.0
81
11.8
45.4
9.1
66
14.8
17.4
7.4
52
6.1
3.2
5.9
34
5.0
5.3
3.8
33
16.3
13.9
3.7
31
9.9
22.0
3.5
25
39.4
5.7
2.8
21
9.9
28.5
2.4
19
-1.6
0.8
2.2
UNICHEM
21
Anti-Infectives
Representative Market
Unichem Laboratories
% Growth
% Share
% Growth
7636
14.9
369
4.8
7.3
UNICHEM
10980
8.3
158
1.4
10.3
Gastroenterologicals
5961
15.2
116
2.0
17.2
Neuro-Psychiatry
3229
14.5
116
3.6
17.4
Musculoskeletals
3938
12.9
34
0.9
16.4
Anti Diabetic
3459
17.3
29
0.8
-0.1
Others
11408
12.6
67
0.6
16.6
TOTAL
46611
12.7
889
1.9
11.1
22
AWACS Data
Quarterly Sales & MAT
Indicators
Unichem (Crs)
Q3 FY 16
24,979
14.3
224
12.7
Q2 FY 16
25,218
15
221
4.6
Q1 FY 16
23,800
14.8
232
15.1
Q4 FY 15
21,984
17.3
212
12.1
21,597
10.3
199
(3.4)
22,122
12.3
215
13.0
20,065
8.8
202
10.7
Q1 FY 14
18,426
8.3
184
6.0
Q2 FY 14
19,357
3.2
187
0.1
Q3 FY 14
19,028
4.9
203
11.9
Q4 FY 14
18,228
6.6
190
4.8
Q1 FY 13
17,016
16.9
174
7.2
Q2 FY 13
18,755
13.6
187
9.2
Q3 FY 13
18,137
8.9
182
8.1
Q4 FY 13
17,083
8.1
181
8.4
Q3 FY 15
Q2 FY 15
Q1 FY 15
UNICHEM
Source: AWACS
23
UNICHEM
APIs
24
UNICHEM
Key risks:
25
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
26
UNICHEM
27
Latin America,
7%
Russia/CIS,
18%
UNICHEM
Latin America,
7%
Russia/CIS,
5%
Africa, 37%
Africa, 41%
28
UNICHEM
Europe, 27%
US / Canada,
73%
US / Canada,
59%
Europe, 41%
29
UNICHEM
Tied with large wholesalers and retail chains for products launched
Total number of ANDAs filed # 35 and development in progress for further filings
Unichems investments in R & D is increasing every year to support the anticipated further
growth
30
UNICHEM
The subsidiary trades across Europe and has extended its operations into South Africa,
and also looking to extend into other geographies
The subsidiary to focus on developing markets for generics and identifying potential
products that can drive the business in in UK and Europe
31
UNICHEM
European Union
Identify and support new players in emerging CEE Markets & Australia
Brazil
32
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
33
UNICHEM
34
9M F Y 2016
Domestic
, 24%
UNICHEM
Exports,
80%
Exports,
76%
ROW,
31%
USA /
Canada,
2%
ROW,
17%
USA /
Canada,
6%
Europe,
67%
Europe,
77%
Total API Revenue : Rs.113 Crores
Unichem Laboratories Ltd
Management Focus
APIs for Generic Markets
Improve Profitability of API Business
Focus on profitable Generic APIs to
New customers in existing Regulated Markets
Penetrate into New Regulated Markets
Achieve cost leadership in 3~4 molecules
UNICHEM
36
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
37
Focus
Unichem has a two fold R&D strategy
Chemical R&D
Centre of Excellence at Goa offering the most conducive environment for value added research
Developed novel, innovative & efficient processes for 45 new generation molecules in various
therapeutic categories
Strong synthesis & analytical team fully equipped with latest facilities
UNICHEM
Formulations R&D
38
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
39
Audit Committee
Shareholders
Grievance
Committee
Compensation
Committee
UNICHEM
Chairman & Managing Director
Divisional Heads
Chairmans Office: IBD & Mkt Strategy, CEO Pharmaceuticals; SBU Heads
- Sales and Marketing; Manufacturing API; Manufacturing Dosage-form;
Research & Development; Quality Assurance & Regulatory; Medical Affairs;
Biosciences; Finance; Commercial & Logistics; Human Resources;
Information Technology
Statutory Auditors
Internal Auditor
40
Agenda
1.
2.
3.
Business Operations
UNICHEM
Domestic Operations
International Operations
API Operations
4.
5.
6.
Financials
41
Particulars
Expenditure:
Material Consumption
% Sales Income
Staff Cost
Other Expenditure
EBITDA
% Total Income
% Total Income
Other Income
Exceptional Items (Gain/-Loss)
Profit before Tax
% Total Income
Income Tax
Net Profit
% Total Income
Exceptional Items
Tax on exceptional item
Net Profit after tax excluding exceptional items
% Total Income
Earning Per Share- Basic-Before Exceptional Item
Earning Per Share- Diluted-After Exceptional Item
18,892
402
15,812
527
9,379
1,721
233
30,626
10,837
35.4%
5,894
10,486
Nine months
ended Dec 31,
2014
19%
-24%
57,167
1,788
50,474
1,841
13%
-3%
7,648
2,302
296
26,585
23%
-25%
-21%
15%
26,731
5,536
868
92,089
23,002
7,318
865
83,499
16%
-24%
0%
10%
10,628
40.0%
4,902
10,211
2%
34,421
37.4%
16,951
29,598
33,126
39.7%
14,509
27,315
4%
11,120
8,550
12.1%
150
2,618
83,738
90.9%
8,352
9.1%
1,683
10.2%
195
2,970
78,114
93.6%
5,385
6.4%
1,572
7%
10,034
10.9%
2,514
7,520
8.2%
353.00
-75.00
7,242
7.9%
6,957
8.3%
1,499
5,458
6.5%
0.00
0.00
5,458
6.5%
44%
8.28
8.26
6.02
6.00
38%
38%
6.02
6.00
33%
33%
20%
3%
844
11.1%
44
872
28,133
91.9%
2,493
8.1%
459
3.2%
65
1,049
26,856
101.0%
(270)
-1.0%
497
-8%
2,952
9.6%
620
2,332
7.6%
353.00
-75.00
2,054
6.7%
227
0.9%
21
206
0.8%
0.00
0.00
206
0.8%
1200%
2.57
2.56
0.23
0.23
1017%
1013%
0.23
0.23
883%
883%
Nine months
ended Dec 31,
2015
% Growth
UNICHEM
Total Expenditure
Operating Income
Three months
ended Dec 31,
2014
3,410
% Total Income
Interest
Depreciation
Three months
ended Dec 31,
2015
-32%
-17%
5%
2852%
1032%
897%
7.98
7.96
% Growth
17%
8%
-23%
-12%
7%
68%
38%
33%
42
Thank You